References
- Meek P, Davis SN, Collin M eta]. Guidelines for nonemergency use of parenteral phenytoin products. Arch. Intern. Med. 159, 2639–2644 (1999).
- ••Good review of the formularyconsiderations for parental phenytoin products and recommendations for use.
- Collin D, Gidal BE, Garnett W Reinfeldt G, Tusch G. Potential under reporting of IV phenytoin adverse events. Ann. Pharmacother. 33, 111–112 (1999).
- Earnest MP, Mazrx JA, Drury LR. Complications of IV phenytoin for acute treatment of seizures. Recommendations for usage. JA/V/A 249, 762–765 (1983).
- Kilarski DJ, Buchanan C, VonBehren L. Soft-tissue damage associated with iv. phenytoin. N. Eng/. J. Med 311, 1186–1187 (1984).
- Spengler RF, Arrowsmith JB, Kilarski DJ, Buchanan C, VonBehren L, Graham DR Severe soft-tissue injury following IV infusion of phenytoin. Patient and drug administration risk factors. Arch. Intern. Med. 148,1329–1333 (1988).
- O'Brien TJ, Meara FM, Matthews H, Vajda FJ. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology57, 1508–1510 (2001).
- •Provides insight into the incidence of phenytoin-induced adverse events.
- Hanna DR. Purple glove syndrome: a complication of IV phenytoin. j Neurosci. NUM: 24, 340–345 (1992).
- Bumeo JG, Andandan JV, Barley GL. A prospective study of the incidence of the purple glove syndrome. 43ilepsia 42(9), 1156–1159 (2001).
- •Provides insight into the incidence of phenytoin-induced adverse events.
- O'Brien TJ, Cascino GD, Therefore, EL, Hanna DR. Incidence and clinical consequences of the purple-glove syndrome in patients receiving IV phenytoin. Neurology51,1034–1039 (1998).
- •Provides insight into the incidence of phenytoin-induced adverse events.
- Burneo JG, Barkley GL. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology58, 1134 (2002).
- •Provides insight into the incidence of phenytoin-induced adverse events.
- Holliday SM, Benfield P, Plosker G. Fosphenytoin. Economic implications of therapy. PharmacoEconomics 14(6), 685–690 (1998).
- Binder L, Trujuillo J, Parker D, Cuetter A. Association of IV phenytoin toxicity with demographic clinical and dosing parameters. Am.j Emerg. Med 14, 398–401 (1996).
- Yoon Y, Jagoda A. New anti-epileptic drugs and preparations. Pharmacol Adv Emer. Med 18(4), 755–765 (2000).
- Cerebyx: Physicians' Desk Reference. Medical Economics Company Inc., NJ, USA, 2619–2622 (2002).
- Pryor FM, Gidal B, Ramsay RE, DeToledo J, Morgan RO. Fosphenytoin: Pharmacokinetics and tolerance of IM loading doses. 43ilepsia 42(2), 245–250 (2001).
- DeToledo JC, Ramsy RE. Fosphenytoin and phenytoin in patients with status epilepticus. Improved tolerability versus increased costs. Drug Safety22 (6), 459–466 (2000).
- Jamerson BD, Dukes GE, Brower KLR, Donn KH, Messenheimer JA, Powell JR Venous irritation related to IV administration of phenytoin versus fosphenytoin. Phannacothempy14, 47–52 (1994) .
- Johnson J, Wrenn K. Inappropriatefosphenytoin use in the ED. Aus. j Emer. Manag. 19(4), 293–294 (2001).
- Anonymous. 2002 Drug Topics Red Book. Medical Economics Company Inc., NJ, USA (2002).
- Armstrong EP, Sauer KA, Downey MJ. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. PharmacoEconomics 19(7), 844–853 (1999).
- •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
- Marchetti A, Magar R, Fischer J, Sloan E, Fischer P A pharmacoeconomic evaluation of iv. fosphenytoin (Cerebyx) versus iv. phenytoin (Dilantin) in hospital emergency departments. Clin. Ther. 18(5), 953–966 (1996).
- •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
- Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy20(8), 908–916 (2000).
- •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
- Graves N. Pharmacoeconomic considerations in treatment options for acute seizures. J. Child Neurol 13,527—S29 (1998).
- Johnson NE, Doyle JJ. A stepwise approach to performing a preliminary pharmacoeconomic analysis: focus on fosphenytoin. P&T611-628 (1996).
- •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.